PSA
43
6
FSLR
50
6
FIS
43
5
HUM
25
4
CF
47
5
RF
44
10
SRE
37
9
BXP
39
5
CHRW
53
2
LH
33
3
IBM
53
2
CMCSA
49
3
CSCO
63
5
NVDA
52
5
GD
42
4
ADBE
50
3
EMR
57
7
VIX
41
-11
CMA
42
3
UHS
50
4
PSA
43
6
FSLR
50
6
FIS
43
5
HUM
25
4
CF
47
5
RF
44
10
SRE
37
9
BXP
39
5
CHRW
53
2
LH
33
3
IBM
53
2
CMCSA
49
3
CSCO
63
5
NVDA
52
5
GD
42
4
ADBE
50
3
EMR
57
7
VIX
41
-11
CMA
42
3
UHS
50
4
Financhill
Back

Regeneron Pharmaceuticals 10K Form

Sell
42

REGN
Regeneron Pharmaceuticals

Last Price:
$701.91
Seasonality Move:
10.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-11-02 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-08-03 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-05-04 10Q REGN/Regeneron Pharmaceuticals Quarterly
2022-11-03 10Q REGN/Regeneron Pharmaceuticals Quarterly
2022-08-03 10Q REGN/Regeneron Pharmaceuticals Quarterly

Receive REGN News And Ratings

See the #1 stock for the next 7 days that we like better than REGN

REGN Financial Statistics

Sales & Book Value

Annual Sales: $13.1B
Cash Flow: $1B
Price / Cash Flow: 24.34
Annual Sales: $266.32
Price / Book: 2.63

Profitability

EPS (TTM): 40.41000
Net Income (TTM): $4.7B
Gross Margin: $11.3B
Return on Equity: 17.19%
Return on Assets: 13.44%

Regeneron Pharmaceuticals Earnings Forecast

Key Regeneron Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 34 years for REGN is 86.16%.
  • The Selling, General & Administrative Expenses for REGN have been equal to 20.06% of Gross Profit Margin.
  • The Research & Development expenses have been 33.84% of Revenue.
  • The Interest Expense is 1.85% of Operating Income.
  • The Net Earning history of REGN is 30.14% of Total Revenues.
  • Per Share Earnings over the last 34 years have been positive in 18 years.

Regeneron Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Biotechnology
Sector: Health Care
Current Symbol: REGN
CUSIP: 75886F
Website: regeneron.com

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 5.28
Quick Ratio: 4.34

Price-to-Earnings

Trailing P/E Ratio: 20.19
Forward P/E Ratio: 15.58

REGN Technical Analysis vs Fundamental Analysis

Sell
42
Regeneron Pharmaceuticals (REGN) is a Sell

Is Regeneron Pharmaceuticals a Buy or a Sell?